Modeling tuberculosis in nonhuman primates

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 12, 2014, Pages

  Scanga, Charles A ^a   Flynn, Joanne L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; NEW DRUG; VACCINE; BCG VACCINE; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CALLITHRIX; DRUG SCREENING; HAPLORHINI; IMAGING; IMMUNOLOGY; IN VIVO STUDY; INOCULATION; LUNG TUBERCULOSIS; MACACA FASCICULARIS; MICROBIOLOGY; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIMATE MODEL; RHESUS MONKEY; TRANSLATIONAL RESEARCH; ANIMAL; DISEASE MODEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOPHYSIOLOGY; PRIMATE DISEASE; TUBERCULOSIS, PULMONARY;

MYCOBACTERIUM TUBERCULOSIS; PRIMATES;

ANIMALS; ANTITUBERCULAR AGENTS; CALLITHRIX; COINFECTION; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; PRIMATE DISEASES; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84937564165     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a018564     Document Type: Article

References (98)

1. Andersen P, Doherty TM. 2005. The success and failure of BCG—Implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.
2. Baram P, Soltysik L, Condoulis W. 1971. The in vitro assay of tuberculin hypersensitivity in Macaca mulatta sensitized with bacille Calmette Guérin cell wall vaccine and-or infected with virulent Mycobacterium tuberculosis. Lab Anim Sci 21: 727-733.
3. Barclay WR, Anacker RL, Brehmer W, Leif W, Ribi E. 1970. Aerosol-induced tuberculosis in subhuman primates and the course of the disease after intravenous BCG vaccination. Infect Immun 2: 574-582.
4. Barclay WR, Busey WM, Dalgard DW, Good RC, Janicki BW, Kasik JE, Ribi E, Ulrich CE, Wolinsky E. 1973. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guérin. Am Rev Resp Dis 107: 351-358.
5. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855.
6. Benson RE, Fremming BD, Young RJ. 1955. A tuberculosis outbreak in a Macaca mulatta colony. Am Rev Tuberc 72: 204-209.
7. Brennan MJ, Stone MR, Evans T. 2012. A rational vaccine pipeline for tuberculosis. Int J Tuberc Lung Dis 16: 1566-1573.
8. Brok HP, Hornby RJ, Griffiths GD, Scott LA, Hart BA. 2001. An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotton-top tamarin. Cytometry 45: 294-303.
9. Budde ML, Greene JM, Chin EN, Ericsen AJ, Scarlotta M, Cain BT, Pham NH, Becker EA, Harris M, Weinfurter JT, et al. 2012. Specific CD8þ T cell responses correlate with control of simian immunodeficiency virus replication in Mauritian cynomolgus macaques. J Virol 86: 7596-7604.
10. Burwitz BJ, Pendley CJ, Greene JM, Detmer AM, Lhost JJ, Karl JA, Piaskowski SM, Rudersdorf RA, Wallace LT, Bimber BN, et al. 2009. Mauritian cynomolgus macaques share two exceptionally common major histocompatibility complex class I alleles that restrict simian immunodeficiency virus-specific CD8þ T cells. J Virol 83: 6011-6019.
11. Caceres N, Llopis I, Marzo E, Prats C, Vilaplana C, de Viedma DG, Samper S, Lopez D, Cardona PJ. 2012. Low dose aerosol fitness at the innate phase of murine infection better predicts virulence amongst clinical strains of Mycobacterium tuberculosis. PloS ONE 7: e29010.
12. Capuano SV 3rd, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, Bissel S, Fuhrman C, Klein E, Flynn JL. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 71: 5831-5844.
13. Chaparas SD, Good RC, Janicki BW. 1975. Tuberculin-induced lymphocyte transformation and skin reactivity in monkeys vaccinated or not vaccinated with Bacille Calmette-Guérin, then challenged with virulent Mycobacterium tuberculosis. Am Rev Respir Dis 112: 43-47.
14. Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, Shen Y, Halliday L, Fortman J, McAllister M, et al. 2009. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 5: e1000392.
15. Chen CY, Yao S, Huang D, Wei H, Sicard H, Zeng G, Jomaa H, Larsen MH, Jacobs WR Jr, Wang R, et al. 2013. Phosphoantigen/IL2 expansion and differentiation of Vg2Vd2 T cells increase resistance to tuberculosis in non-human primates. PLoS Pathog 9: e1003501.
16. Clark SO, Hall Y, Kelly DL, Hatch GJ, Williams A. 2011. Survival of Mycobacterium tuberculosis during experimental aerosolization and implications for aerosol challenge models. J Appl Microbiol 111: 350-359.
17. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. 2003. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
18. Croix DA, Capuano S 3rd, Simpson L, Fallert BA, Fuller CL, Klein EC, Reinhart TA, Murphey-Corb M, Flynn JL. 2000. Effect of mycobacterial infection on virus loads and disease progression in simian immunodeficiency virus-infected rhesus monkeys. AIDS Res Hum Retrovir 16: 1895-1908.
19. Cynamon MH, Klemens SP, Sharpe CA, Chase S. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 43: 1189-1191.
20. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. 2009. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 53: 4879-4884.
21. Diedrich CR, Mattila JT, Klein E, Janssen C, Phuah J, Sturgeon TJ, Montelaro RC, Lin PL, Flynn JL. 2010. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PloS ONE 5: e9611.
22. Diedrich CR, Mattila JT, Flynn JL. 2013. Monocyte-derived IL-5 reduces TNF production by Mycobacterium tuberculosis-specific CD4 T cells during SIV/M. tuberculosis coinfection. J Immunol 190: 6320-6328.
23. Fennelly KP, Jones-Lopez EC, Ayakaka I, Kim S, Menyha H, Kirenga B, Muchwa C, Joloba M, Dryden-Peterson S, Reilly N, et al. 2012. Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med 186: 450-457.
24. Flynn JL, Klein E. 2011. Pulmonary tuberculosis in monkeys. In A color atlas of comparative pulmonary tuberculosis histopathology (ed. Leong VDJ, Dick T), pp. 83-106. CRC, Boca Raton, FL.
25. Flynn JL, Tsenova L, Izzo A, Kaplan G. 2008. Experimental animal models of tuberculosis. In Handbook of tuberculosis: Immunology and cell biology (ed. Kaufmann SHE, Britton WJ), pp. 389-417. Wiley-VCH, Weinheim, Germany.
26. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, Mohaideen N, Ioerger TR, Sacchettini JC, Lipsitch M, et al. 2011. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 43: 482-486.
27. Fourie PB, Odendaal MW. 1983. Mycobacterium tuberculosis in a closed colony of baboons (Papio ursinus). Lab Anim 17: 125-128.
28. Gideon HP, Flynn JL. 2011. Latent tuberculosis: What the host “sees”? Immunol Res 50: 202-212.
29. Good RC. 1968. Biology of the mycobacterioses. Simian tuberculosis: Immunologic aspects. Ann NY Acad Sci 154: 200-213.
30. Good RC. 1984. Diseases in nonhuman primates. In The mycobacteria: A sourcebook (ed. Kubica GP, Wayne LG), pp. 903-921. Dekker, New York
31. Gormus BJ, Blanchard JL, Alvarez XH, Didier PJ. 2004. Evidence for a rhesus monkey model of asymptomatic tuberculosis. J Med Primatol 33: 134-145.
32. Janicki BW, Good RC, Minden P, Affronti LF, Hymes WF. 1973. Immune responses in rhesus monkeys after bacillus Calmette-Guérin vaccination and aerosol challenge with Mycobacterium tuberculosis. Am Rev Respir Dis 107: 359-366.
33. Jensen K, Ranganathan UD, Van Rompay KK, Canfield DR, Khan I, Ravindran R, Luciw PA, Jacobs WR Jr, Fennelly G, Larsen MH, et al. 2012. A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques. Clin Vac Immunol 19: 1170-1181.
34. Keane J. 2004. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin Infect Dis 39: 300-302.
35. Keet DF, Kriek NP, Bengis RG, Grobler DG, Michel A. 2000. The rise and fall of tuberculosis in a free-ranging chacma baboon troop in the Kruger National Park. Onderstepoort J Vet Res 67: 115-122.
36. Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, et al. 2011. Development of therapeutic and prophylactic vaccine against tuberculosis using monkey and transgenic mice models. Hum Vaccin 7: 108-114.
37. Krebs KC, Jin Z, Rudersdorf R, Hughes AL, O’Connor DH. 2005. Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques. J Immunol 175: 5230-5239.
38. Langermans JA, Andersen P, van Soolingen D, Vervenne RA, Frost PA, van der Laan T, van Pinxteren LA, van den Hombergh J, Kroon S, Peekel I, et al. 2001. Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci 98: 11497-11502.
39. Lawn SD, Churchyard G. 2009. Epidemiology of HIV-associated tuberculosis. Curr Opin HIVAIDS 4: 325-333.
40. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, et al. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. New Engl J Med 367: 1508-1518.
41. Lewinsohn DM, Tydeman IS, Frieder M, Grotzke JE, Lines RA, Ahmed S, Prongay KD, Primack SL, Colgin LM, Lewis AD, et al. 2006. High resolution radiographic and fine immunologic definition of TB disease progression in the rhesus macaque. Microbes Infect 8: 2587-2598.
42. Lin PL, Flynn JL. 2010. Understanding latent tuberculosis: A moving target. J Immunol 185: 15-22.
43. Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA, Capuano SV, Klein E, Flynn JL. 2006. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 74: 3790-3803.
44. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, Chiosea I, Capuano SV, Fuhrman C, Klein E, et al. 2009. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 77: 4631-4642.
45. Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, Fuhrman C, Grieser H, Chiosea I, Voitenek NN, Capuano SV, et al. 2010. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 62: 340-350.
46. Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, Klein E, Barry CE III, Flynn JL. 2012a. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci 109: 14188-14193.
47. Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, Bigbee M, Milk L, Gideon HP, Rodgers M, et al. 2012b. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 122: 303-314.
48. Lin PL, Rutledge T, Green AM, Bigbee M, Fuhrman C, Klein E, Flynn JL. 2012c. CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res Hum Retrovir 28: 1693-1702.
49. Lin PL, Coleman T, Carney JP, Lopresti BJ, Tomko J, Fillmore D, Dartois V, Scanga C, Frye LJ, Janssen C, et al. 2013. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 57: 4237-4244.
50. Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, Sacchettini J, Fortune SM, Flynn JL. 2014. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20: 75-79.
51. Luciw PA, Oslund KL, Yang XW, Adamson L, Ravindran R, Canfield DR, Tarara R, Hirst L, Christensen M, Lerche NW, et al. 2011. Stereological analysis of bacterial load and lung lesions in nonhuman primates (rhesus macaques) experimentally infected with Mycobacterium tuberculosis. Am J Physiol Lung Cell Mol Physiol 301: L731-L738.
52. Manca C, Tsenova L, Barry CE III, Bergtold A, Freeman S, Haslett PA, Musser JM, Freedman VH, Kaplan G. 1999. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 162: 6740-6746.
53. Marino S, Linderman JJ, Kirschner DE. 2011. A multifaceted approach to modeling the immune response in tuberculosis. Wiley Interdiscip Rev Syst Biol Med 3: 479-489.
54. Mattila JT, Diedrich CR, Lin PL, Phuah J, Flynn JL. 2011. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J Immunol 186: 3527-3537.
55. Mayhall CG, Lamb VA, Coleman PH. 1981. Infection in rhesus (Macaca mulatta) and squirrel (Saimiri sciureus) monkeys due to Mycobacterium tuberculosis phage type B. Outbreak in a primate colony. J Med Primatol 10: 302-311.
56. McLeay SC, Morrish GA, Kirkpatrick CM, Green B. 2012. The relationship between drug clearance and body size: Systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 51: 319-330.
57. Mehra S, Golden NA, Dutta NK, Midkiff CC, Alvarez X, Doyle LA, Asher M, Russell-Lodrigue K, Monjure C, Roy CJ, et al. 2011. Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus. J Med Primatol 40: 233-243.
58. Michel AL, Hlokwe TM, Espie IW, van Zijll Langhout M, Koeppel K, Lane E. 2013. Mycobacterium tuberculosis at the human/wildlife interface in a high TB burden country. Transbound Emerg Dis 60: 46-52.
59. Min F, Zhang Y, Pan J, Wang J, Yuan W. 2013. Mycobacterium tuberculosis infection in rhesus monkeys (Macaca mulatta) and evaluation of ESAT-6 and CFP10 as immunodiagnostic antigens. Exp Anim 62: 281-293.
60. Mitchison DA, Chang KC. 2009. Experimental models of tuberculosis: Can we trust the mouse? Am J Respir Crit Care Med 180: 201-202.
61. Montali RJ, Mikota SK, Cheng LI. 2001. Mycobacterium tuberculosis in zoo and wildlife species. Rev Sci Tech 20: 291-303.
62. Motzel SL, Schachner RD, Kornegay RW, Fletcher MA, Kanaya B, Gomez JA, Ngai DT-W, Pouch WJ, Washington MV, Handt LA, et al. 2003. Diagnosis of tuberculosis in nonhuman primates. In International perspectives: The future of nonhuman primate resources, pp. 156-159. National Academies Press, Washington, DC.
63. Munoz-Elias EJ, Timm J, Botha T, Chan WT, Gomez JE, McKinney JD. 2005. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun 73: 546-551.
64. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. 2013. The immune response in tuberculosis. Ann Rev Immunol 31: 475-527.
65. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, et al. 2009. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 27: 3267-3270.
66. Ottenhoff TH, Kaufmann SH. 2012. Vaccines against tuberculosis: Where are we and where do we need to go? PLoS Pathog 8: e1002607.
67. Palanisamy GS, Smith EE, Shanley CA, Ordway DJ, Orme IM, Basaraba RJ. 2008. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis 88: 295-306.
68. Panarella ML, Bimes RS. 2010. A naturally occurring outbreak of tuberculosis in a group of imported cynomolgus monkeys (Macaca fascicularis). J Am Assoc Lab Anim Sci 49: 221-225.
69. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. 2012. Tuberculosis and HIV coinfection. PLoS Pathog 8: e1002464.
70. Payne KS, Novak JJ, Jongsakul K, Imerbsin R, Apisitsaowapa Y, Pavlin JA, Hinds SB. 2011. Mycobacterium tuberculosis infection in a closed colony of rhesus macaques (Macaca mulatta). J Am Assoc Lab Anim Sci 50: 105-108.
71. Rahman S, Magalhaes I, Rahman J, Ahmed RK, Sizemore DR, Scanga CA, Weichold F, Verreck F, Kondova I, Sadoff J, et al. 2012. Prime-boost vaccination with rBCG/rAd35 enhances CD8þ cytolytic T-cell responses in lesions from Mycobacterium tuberculosisinfected primates. Mol Med 18: 647-658.
72. Rayner EL, Pearson GR, Hall GA, Basaraba RJ, Gleeson F, McIntyre A, Clark S, Williams A, Dennis MJ, Sharpe SA. 2013. Early lesions following aerosol infection of rhesus macaques (Macaca mulatta) with Mycobacterium tuberculosis strain H37RV. J Comp Pathol 149: 475-485.
73. Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ, Orme IM, Skeiky YA, Alderson MR, Cowgill KD, et al. 2009. Defined tuberculosis vaccine, Mtb72F/ AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci 106: 2301-2306.
74. Ribi E, Anacker RL, Barclay WR, Brehmer W, Harris SC, Leif WR, Simmons J. 1971. Efficacy of mycobacterial cell walls as a vaccine against airborne tuberculosis in the Rheusus monkey. J Infect Dis 123: 527-538.
75. Safi H, Gormus BJ, Didier PJ, Blanchard JL, Lakey DL, Martin LN, Murphey-Corb M, Vankayalapati R, Barnes PF. 2003. Spectrum of manifestations of Mycobacterium tuberculosis infection in primates infected with SIV. AIDS Res Hum Retroviruses 19: 585-595.
76. Sampson SL, Mansfield KG, Carville A, Magee DM, Quitugua T, Howerth EW, Bloom BR, Hondalus MK. 2011. Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. Vaccine 29: 4839-4847.
77. Schmidt LH. 1956. Some observations on the utility of simian pulmonary tuberculosis in defining the therapeutic potentialities of isoniazid. Am Rev Tuberc 74: 138-153; discussion, 153-159.
78. Schmidt LH. 1966. Studies on the antituberculous activity of ethambutol in monkeys. Ann NY Acad Sci 135: 747-758.
79. Schmidt L, Grover A, Hoffmann R. 1959. The comparative therapeutic activities of thiocarbanidin and paraaminosalicylic acid administered alone and in combination with isoniazid. Trans 18th VA-Armed Forces Conf Chemother Tuberculosis 312-317.
80. Schroeder CR. 1938. Acquired tuberculosis in the primate in laboratories and zoological collections. Am J Pub Health Nations Health 28: 469-475.
81. Sharpe SA, Eschelbach E, Basaraba RJ, Gleeson F, Hall GA, McIntyre A, Williams A, Kraft SL, Clark S, Gooch K, et al. 2009. Determination of lesion volume by MRI and stereology in a macaque model of tuberculosis. Tuberculosis 89: 405-416.
82. Sharpe SA, McShane H, Dennis MJ, Basaraba RJ, Gleeson F, Hall G, McIntyre A, Gooch K, Clark S, Beveridge NE, et al. 2010. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vaccine Immunol 17: 1170-1182.
83. Shen Y, Zhou D, Chalifoux L, Shen L, Simon M, Zeng X, Lai X, Li Y, Sehgal P, Letvin NL, et al. 2002a. Induction of an AIDS virus-related tuberculosis-like disease in macaques: A model of simian immunodeficiency virus-mycobacterium coinfection. Infect Immun 70: 869-877.
84. Shen Y, Zhou D, Qiu L, Lai X, Simon M, Shen L, Kou Z, Wang Q, Jiang L, Estep J, et al. 2002b. Adaptive immune response of Vg2Vd2þ T cells during mycobacterial infections. Science 295: 2255-2258.
85. Shin NS, Kwon SW, Han DH, Bai GH, Yoon J, Cheon DS, Son YS, Ahn K, Chae C, Lee YS. 1995. Mycobacterium tuberculosis infection in an orangutan (Pongo pygmaeus). The J Vet Med Sci 57: 951-953.
86. Sugawara I, Sun L, Mizuno S, Taniyama T. 2009. Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculosis 89: 62-67.
87. Tsenova L, Ellison E, Harbacheuski R, Moreira AL, Kurepina N, Reed MB, Mathema B, Barry CE 3rd, Kaplan G. 2005. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis 192: 98-106.
88. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werff NM, Kersbergen A, Ottenhoff TH, Heidt PJ, et al. 2009. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PloS ONE 4: e5264.
89. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76: 2333-2340.
90. Via LE, Schimel D, Weiner DM, Dartois V, Dayao E, Cai Y, Yoon YS, Dreher MR, Kastenmayer RJ, Laymon CM, et al. 2012. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [18F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother 56: 4391-4402.
91. Via LE, Weiner DM, Schimel D, Lin PL, Dayao E, Tankersley SL, Cai Y, Coleman MT, Tomko J, Paripati P, et al. 2013. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 81: 2909-2919.
92. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, Cellona RV, Nazareno JB, Horwitz MA. 1996. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 2: 430-436.
93. Wei H, Wang R, Yuan Z, Chen CY, Huang D, Halliday L, Zhong W, Zeng G, Shen Y, Shen L, et al. 2009. DR W201/ P65 tetramer visualization of epitope-specific CD4 T-cell during M. tuberculosis infection and its resting memory pool after BCG vaccination. PloS ONE 4: e6905.
94. WHO. 2013. Global tuberculosis report 2013. World Health Organization, http://www.who.int/tb/publications/global_report/en/.
95. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53: 1314-1319.
96. Yan G, Zhang G, Fang X, Zhang Y, Li C, Ling F, Cooper DN, Li Q, Li Y, van Gool AJ, et al. 2011. Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol 29: 1019-1023.
97. Zhang J, Ye YQ, Wang Y, Mo PZ, Xian QY, Rao Y, Bao R, Dai M, Liu JY, Guo M, et al. 2011. M. tuberculosis H37Rv infection of Chinese rhesus macaques. J Neuroimmune Pharmacol 6: 362-370.
98. Zhou D, Shen Y, Chalifoux L, Lee-Parritz D, Simon M, Sehgal PK, Zheng L, Halloran M, Chen ZW. 1999. Mycobacterium bovis bacille Calmette-Guérin enhances pathogenicity of simian immunodeficiency virus infection and accelerates progression to AIDS in macaques: A role of persistent T cell activation in AIDS pathogenesis. J Immunol 162: 2204-2216.